Literature DB >> 8487052

Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.

J A Foekens1, W L van Putten, H Portengen, H Y de Koning, B Thirion, J Alexieva-Figusch, J G Klijn.   

Abstract

PURPOSE: Evaluation of the prognostic value of cytosolic PS2 (pS2 protein) and cathepsin D in a large series of breast cancer patients by multivariate analysis taking into account steroid receptors and conventional prognostic factors. PATIENTS AND METHODS: Prognostic factors were analyzed in 710 primary breast cancers (median follow-up, 4 years). PS2 and cathepsin D were measured by radiometric immunoassays. Estrogen receptor (ER) and progesterone receptor (PgR) status were assessed by radioligand binding assays and multiple-point Scatchard analysis.
RESULTS: The best cutoff point for PS2 to discriminate between positive (61% of the tumors) and negative was 2 ng/mg protein (univariate P value in 5-year relapse-free survival = .003). For cathepsin D, no sensible cutoff point could be chosen, since there was a continuous association between the level of cathepsin D and relapse rate (P = .001). In Cox multivariate analysis, relapse rate decreased with age of premenopausal/perimenopausal patients and with PS2 or steroid receptor positivity, and increased with the size of the tumor, the number of positive lymph nodes, and increasing levels of cathepsin D. In analysis for overall survival, age of both premenopausal/perimenopausal and postmenopausal patients, tumor size, the number of positive lymph nodes, ER/PgR, and PS2 were all independently associated with the rate of death. The level of cathepsin D was positively correlated with the rate of death, but this trend was not statistically significant. Separate Cox multivariate analyses for relapse-free survival in subgroups of patients as defined by nodal status showed that the contribution of PS2 and cathepsin D was the strongest in the node-negative subgroup. Node-negative patients with tumors containing PS2 values < or = 2 ng/mg protein and cathepsin D values more than 70 pmol/mg protein experienced a 4.5-fold increase in relapse rate as compared with those with PS2 levels greater than 2 ng/mg protein and cathepsin D levels < or = 30 pmol/mg protein.
CONCLUSION: PS2 and cathepsin D are independent prognostic factors in primary breast cancer and lymph node-negative patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8487052     DOI: 10.1200/JCO.1993.11.5.899

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  15 in total

1.  Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies.

Authors:  S J Reshkin; T Tedone; M Correale; A Mangia; V Casavola; A Paradiso
Journal:  Cell Prolif       Date:  1999 Apr-Jun       Impact factor: 6.831

2.  Expression of the pS2 gene in normal breast tissue.

Authors:  E Hähnel; P Robbins; R Hähnel
Journal:  Breast Cancer Res Treat       Date:  1993-12       Impact factor: 4.872

3.  Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2.

Authors:  R S Rosenberg Zand; D J Jenkins; E P Diamandis
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

Review 4.  Tamoxifen resistance in breast cancer: elucidating mechanisms.

Authors:  L C Dorssers; S Van der Flier; A Brinkman; T van Agthoven; J Veldscholte; E M Berns; J G Klijn; L V Beex; J A Foekens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Genes, chromatin, and breast cancer: an epigenetic tale.

Authors:  L M Mielnicki; H L Asch; B B Asch
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-04       Impact factor: 2.673

6.  Homodimerization and hetero-oligomerization of the single-domain trefoil protein pNR-2/pS2 through cysteine 58.

Authors:  M P Chadwick; B R Westley; F E May
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

7.  Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases.

Authors:  I Soubeyran; J Wafflart; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

8.  Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance.

Authors:  A J Desai; Y A Luqmani; J E Walters; R C Coope; B Dagg; J J Gomm; P E Pace; C N Rees; V Thirunavukkarasu; S Shousha; N P Groome; R Coombes; S Ali
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  pS2 and response to adjuvant hormone therapy in primary breast cancer.

Authors:  F Spyratos; C Andrieu; K Hacène; P Chambon; M C Rio
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

10.  Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

Authors:  J A Foekens; H Portengen; M P Look; W L van Putten; B Thirion; M Bontenbal; J G Klijn
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.